Moffitt Cancer Center
Tampa, FL USA

Our News on Newswise

MEDI4736 Combined with Tremelimumab Results in Acceptable Toxicity, Clinical Activity in Non-Small Cell Lung Cancer Patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as...
28-May-2015 2:05 PM EDT

Component in Green Tea May Help Reduce Prostate Cancer in Men at High Risk

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention – the use of agents to prevent...
28-May-2015 2:05 PM EDT

JAK2 Inhibitor Ruxolitinib has Minimal Toxicity, Promising Efficacy in Chronic Myelomonocytic Leukemia Patients

Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only...
28-May-2015 2:05 PM EDT

Nivolumab Treatment in Melanoma Patients has Manageable Safety Profile, Additional Immunomodulatory Agents Do Not Affect Response Rates

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at...
28-May-2015 2:05 PM EDT

Surgery Followed by Ipilimumab Treatment in Melanoma Patients Improves Survival

Melanoma is predicted to result in approximately 10,000 deaths in 2015. The majority of these deaths are due to advanced stage disease that has spread or metastasized to other sites. The prognosis for patients with metastatic melanoma remains poor,...
20-May-2015 10:00 AM EDT

Differences in Tumor Cell Metabolism Affect Tumor Growth, Invasion, Response to Therapy

Cells within a tumor are not the same; they may have different genetic mutations and different characteristics during growth and throughout treatment. These differences make treating tumors extremely difficult and often lead to tumor recurrence...
19-May-2015 10:00 AM EDT

Androgen Deprivation Therapy May Lead to Cognitive Impairment in Prostate Cancer Patients

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called “chemo brain.” Signs of cognitive...
13-May-2015 10:00 AM EDT

M2Gen® Appoints New Vice President of Strategy and Business Development


Naveen Kumar has been named Vice President of Strategy and Business Development at M2Gen®, Moffitt Cancer Center’s wholly owned, for-profit, informatics solution subsidiary advancing personalized medicine by using high quality tissue, clinical...
12-May-2015 2:00 PM EDT

Our Experts on Newswise

Our experts are coming soon...

Our YouTube Videos